论文部分内容阅读
目的研究前列地尔注射液对慢性充血性心力衰竭(chronic heart failure,CHF)合并肾功能不全的临床效果。方法随机将90例CHF合并肾功能不全的患者分为观察组和对照组各45例,对照组给予常规抗心衰治疗,观察组增加前列地尔注射液治疗,观察心脏血流动力学和肾功能指标改善效果。计量资料两组间比较采用独立样本t检验,组内比较采用配对t检验;计数资料比较采用χ2检验,P<0.05为差异有统计学意义。结果观察组改善心肾功能总有效率为93.33%(35/45),优于对照组的77.78%(42/45),差异有统计学意义(P<0.05)。观察组改善心脏血流动力学指标效果[(41.27±3.26)、(44.83±2.91)%、(43.39±4.05)、(50.72±4.08)mm]均明显优于对照组[(35.13±3.27)、(33.64±4.52)%、(53.39±3.08)、(60.79±4.15)mm],差异均有统计学意义(均P<0.05)。治疗后观察组改善肾功能指标效果[(241.81±37.04)μmol/L、(11.87±3.43)mmol/L、(46.15±3.78)ml/min、(0.11±0.04)g]明显优于对照组[(453.9 6±55.84)μmol/L、(16.42±3.86)mmol/L、(30.46±5.91)ml/min、(0.27±0.03)g],差异均有统计学意义(均P<0.05)。结论前列地尔注射液用于CHF合并肾功能不全的辅助治疗,能明显改善心脏血流动力学,提高心肾功能,且安全性高。
Objective To study the clinical effect of alprostadil injection on chronic heart failure (CHF) with renal insufficiency. Methods A total of 90 CHF patients with renal insufficiency were randomly divided into observation group (45 cases) and control group (45 cases). The control group was given routine anti-heart failure treatment. The observation group was treated with alprostadil injection, and the hemodynamics and kidney Function indicators to improve the effect. Measurement data were compared between two groups using independent samples t test, the group was compared using paired t test; count data were compared using the χ2 test, P <0.05 for the difference was statistically significant. Results The total effective rate of improving heart and kidney function in observation group was 93.33% (35/45), which was better than that in control group (77.78%, 42/45). The difference was statistically significant (P <0.05). The observation group was significantly superior to the control group [(35.13 ± 3.27), [(41.27 ± 3.26), (44.83 ± 2.91)%, (43.39 ± 4.05) and (50.72 ± 4.08) mm] (33.64 ± 4.52)%, (53.39 ± 3.08) and (60.79 ± 4.15) mm, respectively, with significant difference (all P <0.05). After treatment, the effect of improving the renal function of the observation group was significantly better than that of the control group [(241.81 ± 37.04) μmol / L, (11.87 ± 3.43) mmol / L, (46.15 ± 3.78) ml / min, (453.9 ± 55.84) μmol / L, (16.42 ± 3.86) mmol / L, (30.46 ± 5.91) ml / min, (0.27 ± 0.03) g] respectively. There were significant differences between the two groups (all P <0.05). Conclusions Alprostadil injection is an adjuvant therapy for CHF complicated with renal insufficiency, which can significantly improve cardiac hemodynamics, improve heart and kidney function and have high safety.